Delving into the Latest Updates on United Immunity Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Skin and Musculoskeletal Diseases

T-lymphocyte cell therapy

Small molecule drug

CAR-M

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4

Top 5 Drug Type	Count

T-lymphocyte cell therapy	2
Small molecule drug	1
CAR-M	1

Top 5 Target	Count

NY-ESO-1(Cancer/testis antigen 1)	1
TLR(Toll-like receptor)	1

Author: Muraoka, Daisuke ; Miyano, Satoru ; Fujii, Keisuke ; Shiku, Hiroshi ; Akiyoshi, Kazunari ; Tawara, Isao ; Komura, Mitsuhiro ; Imoto, Seiya ; Ikeda, Hiroaki ; Asai, Akira ; Okamori, Kana ; Miyahara, Yoshihiro ; Harada, Naozumi ; Tahara, Yoshiro ; Goto, Masahiro ; Yamaguchi, Rui ; Yagita, Hideo ; Seo, Naohiro ; Sawada, Shin-Ichi ; Hayashi, Tae

100 Deals associated with United Immunity Co. Ltd.

Login to view more data

100 Translational Medicine associated with United Immunity Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Preclinical

Phase 2

1

6

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

UI-201 ( NY-ESO-1 )	Synovial Sarcoma More	Phase 2
UI-102 ( TLR )	Hepatocellular Carcinoma More	Preclinical
UI-103	Solid tumor More	Discovery
US20250255974 Patent Mining	Neoplasms More	Discovery
UI-5 ( HLA-A 24 x MAGEA4 x NY-ESO-1 )	Head and Neck Neoplasms More	Discontinued